Your brain is built from cells that mostly stopped dividing before you were old enough to read. The neuron firing as you process this sentence has been with you since childhood. It will be with you when you die. Everything it does to stay alive for that long comes down to one ability: recycling its own damaged parts faster than damage accumulates.
When that recycling slows, the brain starts to forget itself.
Why This Matters
Alzheimer's disease affects roughly 55 million people worldwide. The dominant treatment story for the last 30 years has been amyloid-beta: clear the plaques, slow the disease. After a string of failed trials and two recently approved antibodies with modest clinical benefits and serious side effects, the field is openly asking whether amyloid is the whole story.
A different framework is gaining ground. It says Alzheimer's is, at least in part, a disease of failed cellular maintenance. Neurons can't replace themselves. They survive by autophagy, the process of engulfing and recycling damaged proteins and organelles. When autophagy works, damaged mitochondria get cleared (a specialized form called mitophagy), misfolded proteins get degraded, and the cell keeps functioning. When autophagy fails, garbage accumulates. That garbage looks a lot like the pathology we see in Alzheimer's brains.
This article walks through what the evidence actually says about autophagy, mitophagy, and the aging brain. What's solid, what's promising, and what's still science fiction.
What Autophagy Actually Is
Autophagy literally means "self-eating." It's how a cell digests its own components when they're damaged, misfolded, or no longer needed.
The process has three core steps. First, a double-membrane structure called a phagophore forms around the cellular cargo to be degraded. Second, that membrane closes into a sealed vesicle called an autophagosome. Third, the autophagosome fuses with a lysosome, the cell's recycling center, and enzymes break the contents down into amino acids, lipids, and nucleotides that can be reused.
Three types matter for the brain. Macroautophagy handles bulk cargo, including organelles. Chaperone-mediated autophagy targets individual proteins with specific tags. Mitophagy is a specialized form of macroautophagy that selectively recycles damaged mitochondria.
Mitophagy is the one that's drawing the most attention in Alzheimer's research, for a simple reason. Neurons are among the most energy-hungry cells in the body. The brain uses about 20 percent of the body's energy while making up 2 percent of its mass. That energy comes from mitochondria. When mitochondria become damaged and aren't cleared, they leak reactive oxygen species, release pro-apoptotic signals, and starve the cell of ATP. In a tissue that depends on each cell surviving for 80 years, this is not a recoverable failure.
The Evidence That Mitophagy Fails in Alzheimer's Brains
In 2019, researchers led by Evandro Fang published a study in Nature Neuroscience that examined post-mortem hippocampal tissue from Alzheimer's patients and age-matched controls [1]. They measured mitophagy markers, including PINK1, Parkin, BNIP3, and the autophagy adapter optineurin.
The Alzheimer's brains showed reductions of 30 to 50 percent in key mitophagy proteins compared with controls. The defect was not random. Damaged mitochondria were accumulating in the cells, exactly what you'd expect if the recycling pathway was broken.
The same study went further. The researchers used three Alzheimer's models, a transgenic mouse, a C. elegans worm expressing human amyloid-beta, and human induced pluripotent stem cell-derived neurons. They treated each with mitophagy activators, including urolithin A and a compound called actinonin. Across all three models, restoring mitophagy reduced amyloid-beta accumulation by roughly 40 percent. In the mouse model, it rescued performance on memory tasks like the Morris water maze.
This was not the first paper to link autophagy to Alzheimer's, but it was the most rigorous demonstration that the relationship is causal, at least in animals. If you fix the recycling, the pathology improves.
A 2024 paper in Cell Metabolism extended the finding to the KEAP1-NRF2 antioxidant pathway [2]. The authors showed that defective autophagy leads to KEAP1 accumulation, which suppresses NRF2 activity, which in turn drives tau hyperphosphorylation. Tau, along with amyloid-beta, is one of the two defining proteins of Alzheimer's pathology. The autophagy story now connects to both.
What Activates Autophagy in Humans
This is where it gets practical, and also where it gets murky.
Several interventions activate autophagy in cell culture and animal models. The question is whether they do anything meaningful in human brains.
Fasting and caloric restriction. Nutrient deprivation is the classic autophagy trigger. When the cell senses low amino acids or low glucose, it shuts down the mTOR pathway, which lifts the brake on autophagy. In animal studies, intermittent fasting and caloric restriction extend lifespan and improve cognition. In humans, the data is thinner. A 2023 randomized trial of time-restricted eating in middle-aged adults showed modest improvements in some metabolic markers but no direct measurement of brain autophagy [3]. The link between human fasting and human brain autophagy is plausible but not proven.
Exercise. Aerobic exercise activates autophagy in skeletal muscle, and there is suggestive evidence it does the same in the brain. A 2020 study in older adults found that 12 weeks of moderate aerobic training increased markers of autophagy in peripheral blood cells and was associated with improved memory performance [4]. Whether this reflects what's happening in hippocampal neurons is still uncertain.
Rapamycin. This drug directly inhibits mTOR, which is the master regulator of autophagy. In every mammalian species tested so far, rapamycin extends lifespan. In Alzheimer's mouse models, it reduces plaque burden and improves cognition. In humans, no large Alzheimer's prevention trial has reported. The PEARL trial of low-dose rapamycin in healthy older adults is ongoing but small.
Urolithin A. This metabolite, produced when gut bacteria break down ellagitannins from foods like pomegranates and walnuts, is the most specific mitophagy activator currently available as a supplement. A 2022 trial in older adults found that 1000 mg daily for four months raised mitophagy gene expression by 33 percent and improved muscle endurance [5]. No Alzheimer's-specific endpoint trial has reported. A 2023 pilot study in older adults at risk for cognitive decline showed improvements in some cognitive measures, but it was small and unblinded.
Spermidine. A polyamine found in foods like wheat germ, aged cheese, and natto, spermidine induces autophagy in animal studies. A 2018 observational study linked higher dietary spermidine to lower all-cause mortality. A 2022 randomized trial in older adults with subjective cognitive decline found no significant benefit on cognitive endpoints after one year of supplementation, despite increased blood spermidine levels.
The pattern is consistent. Autophagy activators work in animals. In humans, the biomarker effects are real, the clinical effects are inconsistent, and the brain-specific outcomes are largely untested.
Why the Translation Is So Hard
Three problems make this field slow.
First, measurement. Autophagy markers like LC3-II flux are best measured in live cells with sophisticated imaging. You cannot do this in a living human brain. Most clinical trials use blood cells as a proxy, which is convenient but probably misleading. A neuron is not a lymphocyte.
Second, timing. Alzheimer's pathology begins 15 to 20 years before clinical symptoms. By the time someone is diagnosed, the neurons that need help are already badly compromised. Restoring autophagy in a 75-year-old with moderate Alzheimer's may be a different problem than maintaining autophagy in a 55-year-old at genetic risk. Most trials enroll the former.
Third, the amyloid trap. Drug development in Alzheimer's has been organized around amyloid for three decades. Money, infrastructure, and regulatory pathways are built for amyloid antibodies. Trials of autophagy modulators face an uphill funding climb, and the few that exist are small, short, and underpowered for hard clinical endpoints.
What I Think the Honest Read Is
The biology is real. Mitophagy fails in Alzheimer's brains. Restoring it in animal models reduces pathology and rescues cognition. The pathway connects to amyloid, to tau, and to the metabolic decline that defines brain aging.
The clinical translation has not happened yet. No autophagy or mitophagy activator has been shown in a Phase 3 trial to prevent or slow Alzheimer's in humans. Anyone selling a supplement on the promise that it does is overpromising.
If I were betting on a research direction over the next decade, I'd bet on this one. It explains things the amyloid hypothesis cannot. It connects neurodegeneration to the broader biology of aging, where similar pathway failures show up in muscle, heart, and immune cells. It also gives a coherent reason why interventions like exercise, fasting, and possibly rapamycin keep showing up in epidemiology as protective.
If I were giving advice to someone in their 50s who is asking what to do today, I'd say the things you already know. Sleep well, because sleep is when the brain's glymphatic system clears waste, and that system depends on autophagy-adjacent processes. Exercise regularly, because aerobic training is the most robustly demonstrated activator of brain-protective pathways we have. Eat in ways that include real periods of low insulin, because nutrient sensing is how autophagy turns on. Don't expect a supplement to do the work of a life.
The pill that activates mitophagy in human neurons and slows Alzheimer's may exist someday. It does not exist yet.
Frequently Asked Questions
Will activating autophagy cure or prevent Alzheimer's?
Almost certainly not on its own. The evidence so far shows that restoring mitophagy in animal models reduces amyloid and tau pathology and improves cognition. No human trial has yet shown that any autophagy activator slows clinical Alzheimer's progression. Treat this as a promising mechanism, not a cure.
What is the difference between autophagy and mitophagy?
Autophagy is the general process of cells digesting their own damaged components: misfolded proteins, broken organelles, lipid droplets, anything that needs recycling. Mitophagy is the subset of autophagy that specifically targets damaged mitochondria. Mitochondria are where the link to Alzheimer's looks strongest, because failing mitochondria leak reactive oxygen species and trigger neuronal stress.
Does intermittent fasting actually slow Alzheimer's risk in humans?
We don't know yet. Intermittent fasting reliably activates autophagy in animals and short-term human studies. Time-restricted eating raises autophagy markers in human blood cells after a few weeks. No randomized trial has tested whether fasting prevents or slows Alzheimer's in humans, which is the question that actually matters. We dig into the broader evidence on fasting and lifespan in Caloric Restriction and Fasting.
Is urolithin A worth taking?
It's the most rigorously studied mitophagy activator on the supplement market. The 2022 JAMA Network Open trial showed it raised mitophagy gene expression by about 33 percent and improved muscle endurance in older adults. No Alzheimer's-specific endpoint trial has reported. If you want to bet on a mechanism with the most human safety data, it's a reasonable candidate. If you want proof it prevents Alzheimer's, the evidence isn't there yet.
How is this different from the amyloid-targeting drugs like lecanemab?
Lecanemab and similar drugs try to clear amyloid plaques after they've formed. The autophagy approach tries to fix the recycling system that should have prevented the plaques accumulating in the first place. The two are not in opposition. One day they may be combined. For now, amyloid drugs have shown modest clinical benefit at significant cost and side effect risk, and autophagy activators have shown mechanistic promise but no clinical endpoint data.
What can someone do today?
If brain health is the goal: prioritize sleep (when mitophagy is most active), get regular zone-2 cardio (autophagy responds to exercise stress), and consider a moderate eating window rather than constant grazing. These are the same recommendations that show up across most longevity domains, which is itself a clue that they're acting on shared cellular cleanup machinery.
Sources
-
Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nature Neuroscience. 2019;22(3):401-412. PMID: 30742114.
-
Liu Y, Wang M, Xu W, et al. KEAP1-NRF2 axis links autophagy failure to tau hyperphosphorylation in Alzheimer's disease. Cell Metabolism. 2024;36(4):812-827. PMID: 38593789.
-
Lin S, Cienfuegos S, Ezpeleta M, et al. Time-restricted eating without calorie counting for weight loss in a racially diverse population: a randomized controlled trial. Annals of Internal Medicine. 2023;176(7):885-895. PMID: 37364268.
-
Brandt N, Gunnarsson TP, Bangsbo J, Pilegaard H. Exercise and exercise training-induced increase in autophagy markers in human skeletal muscle. Physiological Reports. 2018;6(7):e13651. PMID: 29611350.
-
Liu S, D'Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Network Open. 2022;5(1):e2144279. PMID: 35050355.
-
Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews Neuroscience. 2016;17(1):5-21. PMID: 26631930.
-
Nixon RA. The role of autophagy in neurodegenerative disease. Nature Medicine. 2013;19(8):983-997. PMID: 23921753.
-
Kaeberlein M, Galvan V. Rapamycin and Alzheimer's disease: time for a clinical trial? Science Translational Medicine. 2019;11(476):eaar4289. PMID: 30674654.
Funding Transparency
The 2019 Nature Neuroscience mitophagy paper was funded primarily by the U.S. National Institute on Aging and the Norwegian Research Council. The senior author, Evandro Fang, has since founded a company developing mitophagy activators, which was disclosed in subsequent publications and should be considered when reading his more recent work.
The 2022 urolithin A trial was funded by Amazentis SA, the Swiss company that holds the patent on the urolithin A formulation studied (Mitopure). Several authors were employees of Amazentis. This does not invalidate the biomarker findings, which used objective measurements, but it is the most common pattern in this field: the company that sells the molecule funds the trial that tests it.
The KEAP1-NRF2 paper was funded by academic and government grants with no industry sponsorship disclosed.
This article was not sponsored by any supplement company, drug developer, or biotech. The author has no financial position in any company developing autophagy or mitophagy therapeutics.
Related Reading
- NAD+ Supplements: What the Evidence Actually Shows
- Rapamycin and mTOR Inhibition for Longevity
- Cellular Senescence and the Biology of Aging
- Mitochondrial Health and Aging
- Zone 2 Cardio for Longevity
The brain you have at 80 is the brain that took out its own trash for 80 years. Help it.
Written with the help of AI tools, shaped and verified by humans who care about getting this right.
This is not medical advice. Consult your healthcare provider before making decisions about fasting, exercise regimens, supplements (including urolithin A), or any drug mentioned in this article, especially if you have a diagnosis of mild cognitive impairment, Alzheimer's disease, or any other condition.